BR9607066A - Método, composições e conjuntos para aumentar a biodisponibilidade oral de agentes farmacêuticos - Google Patents
Método, composições e conjuntos para aumentar a biodisponibilidade oral de agentes farmacêuticosInfo
- Publication number
- BR9607066A BR9607066A BR9607066-8A BR9607066A BR9607066A BR 9607066 A BR9607066 A BR 9607066A BR 9607066 A BR9607066 A BR 9607066A BR 9607066 A BR9607066 A BR 9607066A
- Authority
- BR
- Brazil
- Prior art keywords
- agents
- target
- oral
- administration
- agent
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 10
- 239000002246 antineoplastic agent Substances 0.000 abstract 2
- 238000011260 co-administration Methods 0.000 abstract 2
- 239000003623 enhancer Substances 0.000 abstract 2
- 230000002708 enhancing effect Effects 0.000 abstract 2
- 230000008685 targeting Effects 0.000 abstract 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 abstract 1
- GNGBSKIQPUCELM-YBAOVNABSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-33-[(e,2r)-2-methylhex-4-enyl]-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29, Chemical compound CC[C@@H]1NC(=O)[C@H](C[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-YBAOVNABSA-N 0.000 abstract 1
- ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 abstract 1
- 229930105110 Cyclosporin A Natural products 0.000 abstract 1
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 abstract 1
- GNGBSKIQPUCELM-UHFFFAOYSA-N Cyclosporin F Natural products CCC1NC(=O)C(CC(C)CC=CC)N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C1=O GNGBSKIQPUCELM-UHFFFAOYSA-N 0.000 abstract 1
- 108010036949 Cyclosporine Proteins 0.000 abstract 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 229940034982 antineoplastic agent Drugs 0.000 abstract 1
- 229960001265 ciclosporin Drugs 0.000 abstract 1
- 108010019594 cyclosporin D Proteins 0.000 abstract 1
- 108010019252 cyclosporin F Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- 229960004125 ketoconazole Drugs 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
"MéTODO, COMPOSIçõES E CONJUNTOS PARA AUMENTAR A BIODISPONIBILIDADE ORAL DE AGENTES FARMACêUTICOS". Método para aumentar a biodisponibilidade quando da administração oral de uma gente alvo farmacologicamente ativo, particularmente um agente antitumoral ou anti-neoplástico, que apresenta biodisponibilidade oral deficiente ou inconstante (p.ex., paclitaxel, docetaxel ou etoposida), compreende a co-administração oral a um paciente mamífero do agente alvo e um agente intensificador de biodisponibilidade oral (p.ex., ciclosporina A, ciclosporina D, ciclosporina F ou cetoconazol). O agente intensificador pode ser administrado oralmente de 0,5-24 h antes da administração oral de uma ou mais doses do agente alvo, substancialmente simultaneamente com o agente alvo ou tanto antes de e substancialmente simultaneamente com o agente alvo. Método para tratar pacientes mamíferos acometidos de doenças que reagem a agentes alvo com biodisponibilidade oral deficiente, bem como formas de administração oral que contêm tais agentes alvo, combinações de formas de administração oral que contêm agentes intensificadores de biodisponibilidade e agentes 1alvo, conjuntos contendo formas de administração de agentes intensificador e alvo e informações de dosagem para a co-administração dos mesmos, também estão descritos.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US707195P | 1995-10-26 | 1995-10-26 | |
| US08/608,776 US5968972A (en) | 1995-10-26 | 1996-02-29 | Method for increasing the oral bioactivity of pharmaceutical agents |
| US08/733,142 US6245805B1 (en) | 1995-10-26 | 1996-10-16 | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| PCT/IB1996/001485 WO1997015269A2 (en) | 1995-10-26 | 1996-10-24 | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9607066A true BR9607066A (pt) | 2002-12-10 |
Family
ID=27358262
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9607066-8A BR9607066A (pt) | 1995-10-26 | 1996-10-24 | Método, composições e conjuntos para aumentar a biodisponibilidade oral de agentes farmacêuticos |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US6245805B1 (pt) |
| EP (1) | EP0794794B1 (pt) |
| JP (1) | JP3361102B2 (pt) |
| CN (2) | CN1119146C (pt) |
| AT (1) | ATE311903T1 (pt) |
| AU (1) | AU698142B2 (pt) |
| BR (1) | BR9607066A (pt) |
| CA (1) | CA2205534A1 (pt) |
| CZ (1) | CZ202897A3 (pt) |
| DE (2) | DE794794T1 (pt) |
| DK (1) | DK0794794T3 (pt) |
| ES (1) | ES2109899T3 (pt) |
| HK (1) | HK1001960A1 (pt) |
| HU (1) | HUP9900457A3 (pt) |
| IL (1) | IL121160A0 (pt) |
| MX (1) | MX9704629A (pt) |
| NO (1) | NO321091B1 (pt) |
| NZ (1) | NZ324801A (pt) |
| PL (2) | PL188281B1 (pt) |
| RU (1) | RU2217135C2 (pt) |
| SK (1) | SK85997A3 (pt) |
| WO (1) | WO1997015269A2 (pt) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5439686A (en) * | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
| US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| US6964946B1 (en) * | 1995-10-26 | 2005-11-15 | Baker Norton Pharmaceuticals, Inc. | Oral pharmaceutical compositions containing taxanes and methods of treatment employing the same |
| US6245805B1 (en) | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| BR9809694A (pt) * | 1997-05-27 | 2000-10-03 | Baker Norton Pharma | Processo e composição para administração de taxanos oralmente a pacientes humanos |
| US8853260B2 (en) | 1997-06-27 | 2014-10-07 | Abraxis Bioscience, Llc | Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof |
| GB9718903D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Method,compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| AU9785698A (en) | 1997-10-02 | 1999-04-27 | Microcide Pharmaceuticals, Inc. | Fungal efflux pump inhibitors |
| CN100358529C (zh) * | 1998-06-29 | 2008-01-02 | 洛杉矶儿童医院 | 全反式视黄酰胺和神经酰胺降解抑制剂的制药用途 |
| EP1189637B1 (en) | 1999-05-17 | 2006-08-23 | Cancer Research Ventures Limited | Compositions for improving bioavailability of orally administered drugs |
| EP1479382A1 (en) * | 1999-06-18 | 2004-11-24 | IVAX Research, Inc. | Oral pharmaceutical compositions containing taxanes and methods for treatment employing the same |
| GB9920548D0 (en) * | 1999-08-31 | 1999-11-03 | Rhone Poulenc Rorer Sa | Treatment of hepatocellular carcinoma |
| US20020147197A1 (en) * | 1999-10-08 | 2002-10-10 | Newman Michael J. | Methods and compositions for enhancing pharmaceutical treatments |
| CZ20021484A3 (cs) * | 1999-10-27 | 2003-12-17 | Baker Norton Pharmaceuticals, Inc. | Farmaceutický prostředek obsahující taxan pro orální podávání lidem |
| US6638973B2 (en) * | 2000-02-02 | 2003-10-28 | Fsu Research Foundation, Inc. | Taxane formulations |
| US6750246B1 (en) | 2000-02-03 | 2004-06-15 | Bristol-Myers Squibb Company | C-4 carbonate taxanes |
| AU2001236009A1 (en) * | 2000-03-02 | 2001-09-12 | Hisamitsu Pharmaceutical Co. Inc. | P-glycoprotein modifier-containing medicinal compositions to be delivered to thelarge intestine |
| US6362217B2 (en) | 2000-03-17 | 2002-03-26 | Bristol-Myers Squibb Company | Taxane anticancer agents |
| US20030144312A1 (en) * | 2001-10-30 | 2003-07-31 | Schoenhard Grant L. | Inhibitors of ABC drug transporters in multidrug resistant cancer cells |
| BR0213989A (pt) * | 2001-11-07 | 2005-03-01 | Pharmacia Corp | Métodos para promover a absorção e acúmulo nuclear de poliamidas em células eucarióticas |
| PL374283A1 (en) * | 2001-12-20 | 2005-10-03 | Bristol-Myers Squibb Company | Pharmaceutical compositions of orally active taxane derivatives having enhanced bioavailability |
| JP2006514698A (ja) * | 2002-10-30 | 2006-05-11 | スフェリックス， インコーポレイテッド | ナノ粒子生物活性物質 |
| US20050113324A1 (en) * | 2003-01-15 | 2005-05-26 | Bondarev Igor E. | Modulation of line-1 reverse transcriptase |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| GB2423928B (en) * | 2004-11-16 | 2008-04-09 | Efflux Technology Inc | Methods and compositions for treating pain |
| US20070087977A1 (en) * | 2004-11-16 | 2007-04-19 | Wendye Robbins | Methods and compositions for treating pain |
| US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
| US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
| CA2625700A1 (en) * | 2005-10-14 | 2007-04-26 | Allergan, Inc. | Prevention and treatment of drug-associated ocular side effects with a cyclosporin |
| CN101677987A (zh) * | 2007-06-22 | 2010-03-24 | 赛多斯有限责任公司 | 不含吐温80的多西他赛的增溶制剂 |
| US20090111736A1 (en) * | 2007-10-29 | 2009-04-30 | Sri International | Orally-Absorbed Solid Dose Formulation for Vancomycin |
| CN101559059B (zh) * | 2008-04-16 | 2012-12-05 | 北京万全阳光医学技术有限公司 | 一种含有盐酸阿米洛利的药物组合物及其制备方法 |
| US20090318561A1 (en) * | 2008-06-23 | 2009-12-24 | Mutual Pharmaceutical Company, Inc. | Colchicine products, method of manufacture, and methods of use |
| JP2011530532A (ja) * | 2008-08-07 | 2011-12-22 | シェーリング コーポレイション | 固体分子分散物中のｈｃｖプロテアーゼインヒビターの薬学的処方物 |
| US7820681B1 (en) | 2009-01-14 | 2010-10-26 | Mutual Pharmaceutical Company, Inc. | Methods for concomitant administration of colchicine and a second active agent |
| US20110046228A1 (en) * | 2009-08-20 | 2011-02-24 | Mutual Pharmaceutical Company, Inc. | Methods for administration of colchicine with grapefruit juice |
| US8541465B2 (en) * | 2009-10-19 | 2013-09-24 | Scidose, Llc | Docetaxel formulations with lipoic acid and/or dihydrolipoic acid |
| US7772274B1 (en) | 2009-10-19 | 2010-08-10 | Scidose, Llc | Docetaxel formulations with lipoic acid |
| US8912228B2 (en) | 2009-10-19 | 2014-12-16 | Scidose Llc | Docetaxel formulations with lipoic acid |
| US20110092579A1 (en) * | 2009-10-19 | 2011-04-21 | Scidose Llc | Solubilized formulation of docetaxel |
| US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
| SG185389A1 (en) | 2010-05-03 | 2012-12-28 | Teikoku Pharma Usa Inc | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| US20120295932A1 (en) * | 2011-05-17 | 2012-11-22 | Western Connecticut Health Network, Inc. | Method for the treatment of cancer |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| TWI838700B (zh) | 2015-09-30 | 2024-04-11 | 香港商慧源香港創新有限公司 | 口服紫杉烷組合物及方法 |
| CN107843966B (zh) | 2016-09-18 | 2021-05-04 | 中芯国际集成电路制造(上海)有限公司 | 用于装配微透镜阵列组件的方法和系统 |
| CN106822085B (zh) * | 2016-12-17 | 2020-03-17 | 浙江省人民医院 | 表达trail的溶瘤腺病毒联合槲皮素在抑制肝癌癌细胞增殖中的用途 |
| US20230149377A1 (en) * | 2018-11-21 | 2023-05-18 | Elevar Therapeutics, Inc. | Pharmaceutical methods |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5118493A (en) | 1986-05-02 | 1992-06-02 | Brigham And Women's Hospital | Composition having reduced nephrotoxocity comprising a fatty acid containing component and cyclosporine |
| ES2059558T3 (es) | 1987-06-17 | 1994-11-16 | Sandoz Ag | Ciclosporins y su uso como productos farmaceuticos. |
| CA1340821C (en) | 1988-10-06 | 1999-11-16 | Nobuyuki Fukazawa | Heterocyclic compounds and anticancer-drug reinforcing agents containing them as effective components |
| JP2525478B2 (ja) | 1989-03-01 | 1996-08-21 | 帝人株式会社 | 安定性の改良された活性型ビタミンｄ▲下３▼類固型製剤 |
| US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
| US5114951A (en) | 1989-04-11 | 1992-05-19 | Burroughs Wellcome Company | Agents for combating multiple drug resistance |
| US5208238A (en) | 1989-06-19 | 1993-05-04 | Burroughs Wellcome Company | Agents for potentiating the effects of antitumor agents and combating multiple drug resistance |
| GB8914040D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8914061D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8914060D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8914062D0 (en) | 1989-06-19 | 1989-08-09 | Wellcome Found | Agents for potentiating the effects of antitumour agents and combating multiple drug resistance |
| GB8926715D0 (en) | 1989-11-28 | 1990-01-17 | Haessle Ab | Improvements relating to the administration of pharmaceutical agents |
| JPH06504772A (ja) | 1990-12-18 | 1994-06-02 | ザ ウエルカム ファウンデーション リミテッド | 抗癌剤の薬効を増強し抗多剤耐性を有する薬剤 |
| HUT68856A (en) | 1991-01-11 | 1995-08-28 | Glaxo Lab Sa | Acridine derivatives, pharmaceutical compositions comprising the same compouds as effective substances and a process for producing the compounds and the pharmaceutical compositions |
| US5166207A (en) | 1991-06-17 | 1992-11-24 | Neurotherapeutics, Inc. | Method for enhancing the systemic delivery of dextromethorphan for the treatment of neurological disorders |
| FR2678833B1 (fr) * | 1991-07-08 | 1995-04-07 | Rhone Poulenc Rorer Sa | Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes. |
| US5750561A (en) | 1991-07-08 | 1998-05-12 | Rhone-Poulenc Rorer, S.A. | Compositions containing taxane derivatives |
| CA2149150C (en) | 1992-11-27 | 2000-08-01 | David R. Carver | Injectable taxol composition with improved stability |
| FR2698543B1 (fr) | 1992-12-02 | 1994-12-30 | Rhone Poulenc Rorer Sa | Nouvelles compositions à base de taxoides. |
| US5646176A (en) | 1992-12-24 | 1997-07-08 | Bristol-Myers Squibb Company | Phosphonooxymethyl ethers of taxane derivatives |
| US6096331A (en) | 1993-02-22 | 2000-08-01 | Vivorx Pharmaceuticals, Inc. | Methods and compositions useful for administration of chemotherapeutic agents |
| US5387685A (en) | 1993-07-16 | 1995-02-07 | American Cyanamid Co | MDR reversal agents |
| CA2129288C (en) * | 1993-08-17 | 2000-05-16 | Jerzy Golik | Phosphonooxymethyl esters of taxane derivatives |
| TW406020B (en) * | 1993-09-29 | 2000-09-21 | Bristol Myers Squibb Co | Stabilized pharmaceutical composition and its method for preparation and stabilizing solvent |
| US5610173A (en) * | 1994-01-07 | 1997-03-11 | Sugen, Inc. | Formulations for lipophilic compounds |
| US5567592A (en) * | 1994-02-02 | 1996-10-22 | Regents Of The University Of California | Screening method for the identification of bioenhancers through the inhibition of P-glycoprotein transport in the gut of a mammal |
| US5565478A (en) * | 1994-03-14 | 1996-10-15 | The United States Of America As Represented By The Department Of Health & Human Services | Combination therapy using signal transduction inhibitors with paclitaxel and other taxane analogs |
| FR2718963B1 (fr) | 1994-04-25 | 1996-05-24 | Rhone Poulenc Rorer Sa | Nouvelle composition pharmaceutique à base de taxoïdes. |
| US5616330A (en) * | 1994-07-19 | 1997-04-01 | Hemagen/Pfc | Stable oil-in-water emulsions incorporating a taxine (taxol) and method of making same |
| US5681846A (en) * | 1995-03-17 | 1997-10-28 | Board Of Regents, The University Of Texas System | Extended stability formulations for paclitaxel |
| US5716928A (en) * | 1995-06-07 | 1998-02-10 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| US5665386A (en) * | 1995-06-07 | 1997-09-09 | Avmax, Inc. | Use of essential oils to increase bioavailability of oral pharmaceutical compounds |
| GB9514878D0 (en) * | 1995-07-20 | 1995-09-20 | Danbiosyst Uk | Vitamin E as a solubilizer for drugs contained in lipid vehicles |
| US6395770B1 (en) * | 1995-10-26 | 2002-05-28 | Baker Norton Pharmaceuticals, Inc. | Method and compositions for administering taxanes orally to human patients |
| US6245805B1 (en) * | 1995-10-26 | 2001-06-12 | Baker Norton Pharmaceuticals, Inc. | Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents |
| US5968972A (en) * | 1995-10-26 | 1999-10-19 | Baker Norton Pharmaceuticals, Inc. | Method for increasing the oral bioactivity of pharmaceutical agents |
| CA2221444A1 (en) | 1996-01-31 | 1997-08-07 | Steven B. Hansel | A method of making pharmaceutically active taxanes orally bioavailable |
| US5877205A (en) * | 1996-06-28 | 1999-03-02 | Board Of Regents, The University Of Texas System | Parenteral paclitaxel in a stable non-toxic formulation |
| US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
| IL131217A0 (en) * | 1998-03-10 | 2001-01-28 | Napro Biotherapeutics Inc | Novel methods and compositions for delivery of taxanes |
| US6136846A (en) * | 1999-10-25 | 2000-10-24 | Supergen, Inc. | Formulation for paclitaxel |
-
1996
- 1996-10-16 US US08/733,142 patent/US6245805B1/en not_active Expired - Fee Related
- 1996-10-24 DE DE0794794T patent/DE794794T1/de active Pending
- 1996-10-24 JP JP51644997A patent/JP3361102B2/ja not_active Expired - Fee Related
- 1996-10-24 DK DK96943268T patent/DK0794794T3/da active
- 1996-10-24 CN CN96191685A patent/CN1119146C/zh not_active Expired - Fee Related
- 1996-10-24 EP EP96943268A patent/EP0794794B1/en not_active Expired - Lifetime
- 1996-10-24 AU AU12056/97A patent/AU698142B2/en not_active Ceased
- 1996-10-24 ES ES96943268T patent/ES2109899T3/es not_active Expired - Lifetime
- 1996-10-24 IL IL12116096A patent/IL121160A0/xx unknown
- 1996-10-24 SK SK859-97A patent/SK85997A3/sk unknown
- 1996-10-24 CN CNB031458033A patent/CN100335123C/zh not_active Expired - Fee Related
- 1996-10-24 CA CA002205534A patent/CA2205534A1/en not_active Abandoned
- 1996-10-24 WO PCT/IB1996/001485 patent/WO1997015269A2/en active IP Right Grant
- 1996-10-24 AT AT96943268T patent/ATE311903T1/de not_active IP Right Cessation
- 1996-10-24 MX MX9704629A patent/MX9704629A/es not_active IP Right Cessation
- 1996-10-24 RU RU97112888/14A patent/RU2217135C2/ru not_active IP Right Cessation
- 1996-10-24 HU HU9900457A patent/HUP9900457A3/hu unknown
- 1996-10-24 CZ CZ972028A patent/CZ202897A3/cs unknown
- 1996-10-24 DE DE69636531T patent/DE69636531T2/de not_active Expired - Fee Related
- 1996-10-24 BR BR9607066-8A patent/BR9607066A/pt not_active Application Discontinuation
- 1996-10-24 PL PL96321791A patent/PL188281B1/pl not_active IP Right Cessation
- 1996-10-24 NZ NZ324801A patent/NZ324801A/xx unknown
- 1996-10-24 PL PL368566A patent/PL192544B1/pl unknown
-
1997
- 1997-06-25 NO NO19972968A patent/NO321091B1/no unknown
-
1998
- 1998-02-11 HK HK98101042A patent/HK1001960A1/xx not_active IP Right Cessation
-
2001
- 2001-04-10 US US09/829,846 patent/US6610735B2/en not_active Expired - Fee Related
-
2002
- 2002-09-12 US US10/242,050 patent/US6818615B2/en not_active Expired - Fee Related
-
2004
- 2004-03-15 US US10/800,990 patent/US7041640B2/en not_active Expired - Fee Related
-
2005
- 2005-04-13 US US11/105,081 patent/US20050238634A1/en not_active Abandoned
-
2006
- 2006-08-14 US US11/503,607 patent/US20070060635A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9607066A (pt) | Método, composições e conjuntos para aumentar a biodisponibilidade oral de agentes farmacêuticos | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| BR9909672A (pt) | uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão | |
| KR960700742A (ko) | 아토피성질환 치료약(atopic disease remedy) | |
| RU2003121768A (ru) | Способ, лекарственная форма и наборы для повышения пероральной биологической доступности фармацевтических агентов | |
| BR9611802A (pt) | Composições farmacêuticas | |
| DE69731610D1 (de) | Orale verabreichung wirksamer mengen von hyaluronsäure | |
| CO5251419A1 (es) | Composiciones nanoparticuladas de eplerenona | |
| BR0109779A (pt) | Soluções moleculares hidrofìlicas dispersas de carvedilol | |
| HUP9903732A2 (hu) | cGMP-szintjét növelő szerek alkalmazása a jóindulatú prosztatatúltengés kezelésére szolgáló gyógyszerkészítmények előállítására | |
| BRPI0008228B8 (pt) | composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes | |
| BR9608435A (pt) | Metodo para medicação do sistema de controle inflatório e de reações inflamatórias adversas e para produção de composto para o tratamento da patologia de reações inflamatórias adversas. | |
| HUP0104410A2 (hu) | Ateroszklerózis megelőzésére és/vagy kezelésére szolgáló gyógyszerkészítmények | |
| BR9709838A (pt) | Regime de administração que fornece um perfil de plasma no sangue de um inibidor de h+,k+-atpase composição farmacêutica oral uso da mesma e de inibidor h+,k+-atpase e processos para melhorar a inibição de secreção de ácido gástrico e o efeito terapêutico no tratamento de perturbações gastrintestinais e para receber um perfil estendido de plasma de um inibidor de h+,k+-atpase | |
| HUP0003546A2 (hu) | Kompozíciók taxánok orális adagolására embereknek | |
| KR970061244A (ko) | 치매 치료용 약학 조성물 | |
| IT1270846B (it) | Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica. | |
| ES2139842T3 (es) | Uso de la melatonina para tratar a pacientes que sufren drogodependencia. | |
| ATE311928T1 (de) | (-)-pseudoephedrin als sympathomimetisches arzneimittel | |
| DK1027053T3 (da) | Fremgangsmåde til forebyggelse af nefrotoksicitet forårsaget af cyclosporiner eller tacrolimuser | |
| ATE91890T1 (de) | Herstellung eines arzneimittels gegen arthritis und rheumatismus. | |
| ATE293445T1 (de) | Herstellung reiner stereoisomere von tricyclo- (5.2.1.0(2.6) )-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
| Abernethy et al. | Oral 5-fluorouracil in psoriasis: pharmacokinetic-pharmacodynamic relationships | |
| HUP9800623A2 (hu) | (+)-O-demetil-tramadol felhasználása fájdalomcsillapító hatású orális gyógyszerkészítmények előállítására |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] | ||
| B12B | Appeal against refusal [chapter 12.2 patent gazette] |